News | Structural Heart | May 25, 2022

ŌNŌCOR Receives FDA Clearance for Novel Endovascular Retrieval Technology

The ŌNŌ is intended to simplify bailout procedures in the expanding world of structural heart disease interventions

The ŌNŌ is intended to simplify bailout procedures in the expanding world of structural heart disease interventions

May 25, 2022 — ŌNŌCOR LLC, a leader in endovascular safety technology, today announced it has received 510(k) U.S. Food and Drug Administration (FDA) clearance for its ŌNŌ retrieval system, the first major advance in endovascular bailout technology in decades. This comes at a time when endovascular closure procedures are rapidly expanding in scope and complexity around the world.

“The FDA clearance of the ŌNŌ is a significant milestone for safety innovation in catheter- based therapies,” said Matthew J. Gillespie, M.D., co-founder of ŌNŌCOR. “I’ve watched the scope and complexity of endovascular devices and procedures increase rapidly over the last 20 years and have been struck by the absence of an equal advancement in rescue technologies. The ŌNŌ was invented to help interventionalists ensure the promise of safety that they make to their patients on a daily basis.”

Catheter-based closure procedures, which are touted as safer alternatives to open-heart surgical procedures, are now routinely performed in cardiac catheterization labs and endovascular suites. Interventions such as patent foramen ovale (PFO) closure, left atrial appendage (LAA) occlusion, atrial septal defect (ASD) closure, ventricular septal defect (VSD) closure, and patent ductus arteriosus closure, among others, are performed tens of thousands of times per year globally.

Though generally safe, these complex procedures carry unavoidable risks. Problems such as device misplacement, embolization, or improperly functioning implants can necessitate a rescue procedure for device removal. The ability to safely retrieve and remove a wayward device is paramount to ensuring the promise of safety currently ascribed to these proliferating endovascular therapies.

The ŌNŌ is a novel device designed to receive, align, compress, and remove suboptimal or embolized devices from the vascular system through 12Fr or larger sheaths. ŌNŌ was designed to be intuitive to use and is compatible with commercially available vascular sheaths and endovascular snares.

“We believe that every interventionalist performing a catheter-based procedure should have an ŌNŌ device at hand for the inevitable occasion when a problem occurs,” said Mark Piper, CEO of ŌNŌCOR. “Mitigating the consequences of even rare events should be paramount for every physician.”

ŌNŌCOR plans for commercial launch of the ŌNŌ across the United States beginning in 2022.

For more information: www.onocorvascular.com


Related Content

News | Endovascular Aortic Repair

October 26, 2022 — Thousands of people have new hope for treatment of thoracic aortic arch disease and University ...

Home October 26, 2022
Home
News | Endovascular Aortic Repair

March 22, 2022 – A retrospective evaluation of 600 fenestrated-branched endovascular aortic repairs for the treatment of ...

Home March 22, 2022
Home
News | Endovascular Aortic Repair

February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of ...

Home February 18, 2022
Home
News | Endovascular Aortic Repair

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a ...

Home May 12, 2021
Home
News | Endovascular Aortic Repair

February 23, 2021 — Medtronic has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent ...

Home February 23, 2021
Home
News | Endovascular Aortic Repair

January 31, 2020 – The Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) released new reporting ...

Home January 31, 2020
Home
News | Endovascular Aortic Repair

January 29, 2020 – The presence of a blood clot on the wall of the aorta in people with abdominal aortic aneurysms (AAA) ...

Home January 29, 2020
Home
News | Endovascular Aortic Repair

November 7, 2019 — The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for ...

Home November 11, 2019
Home
News | Endovascular Aortic Repair

November 21, 2018 — New research in the December edition of the Journal of Vascular Surgery suggests significant ...

Home November 21, 2018
Home
News | Endovascular Aortic Repair

October 8, 2018 — Endologix Inc. received notice that the U.S. Food and Drug Administration (FDA) has classified a ...

Home October 08, 2018
Home
Subscribe Now